Drug-induced QT interval prolongation: mechanisms and clinical management - Wikidata - awgldk - TriplyDB

Drug-induced QT interval prolongation: mechanisms and clinical management

Drug-induced QT interval prolongation: mechanisms and clinical management

http://www.wikidata.org/entity/Q33949538

about

Ventricular repolarization measures for arrhythmic risk stratification A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.Cardiac risks associated with antibiotics: azithromycin and levofloxacin Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine.QTc interval in young Gujarati hypertensives: Effect of disease, antihypertensive monotherapy, and coexisting risk factors.Drug-associated arrhythmia in the military patient.Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.Risk factors for QTc-prolongation: systematic review of the evidence.Development of Safe Drugs: The hERG Challenge.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.First-generation antipsychotics and QTc: any role for mediating variables?Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.[Rational use of antibiotics].Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.Drug-Induced QT Prolongation And Torsades de Pointes.Trigger vs. Substrate: Multi-Dimensional Modulation of QT-Prolongation Associated Arrhythmic Dynamics by a hERG Channel Activator.Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.Assessment of Prescribing and Monitoring Habits for Patients Taking an Antiarrhythmic and Concomitant QTc-Prolonging Antibiotic.Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.Organ-on-a-Chip Systems for Women's Health Applications.George Ralph Mines (1886-1914): the dawn of cardiac nonlinear dynamics.Risk factors for QTc interval prolongation.The Impact of Cirrhosis and Prescription Medications on QTc Interval Before and After Liver Transplantation.

P2860

Q26769982-AB1DC031-C71A-4626-8E9B-8F548A464C89 Q33167296-3BA72996-8091-4074-B020-37CDE959CC57 Q35502601-87F2886C-46D5-4BB9-B801-39DB2D0C92CD Q37124633-8CD9EF0B-1AEF-4C9D-BE31-5C30ABA8D012 Q37591595-3DEE4701-F75D-4FA5-BA41-82085E657D0A Q38566602-5D5585D7-4640-4E43-833E-957819FE3D25 Q38632775-B0E6226F-0967-4406-BFAC-F96B1FC53CA2 Q38667854-FCAA092B-D5FF-4238-AF46-A87CAB7E53A6 Q39052301-7E216440-DC59-4148-937B-1B45371086C0 Q39280559-974E9600-1A3F-42B6-896B-4B1EB93EF350 Q39350678-57FADC4A-136D-450C-99DC-D114A7936B61 Q39721569-DB808517-2BCF-4719-9969-BB10517E78AB Q40108685-4C1527C4-91D0-405A-BC17-5A34467A9844 Q40181568-E01F551F-FE2A-4154-AD36-E88A26C7F9C3 Q40651143-C5C5715C-7D01-4806-8920-FA4D8DAFB302 Q40661028-3DEE6AC6-254E-4621-84A9-B61F2550F2E5 Q41064858-80B2E21A-737A-4B87-ACEC-B993C7BE67F7 Q42372777-49F89A04-3539-4A7F-B784-5E2BB2288DB5 Q42650229-1F45E17C-1D73-4946-97C8-CB0929665F44 Q44587107-7E473E88-F100-4708-8C83-E392230C05AA Q47159971-1E8FF4F2-4F1D-49E6-9293-198BCB0EDF73 Q47346313-094FFFBD-CA99-4F86-89B7-4C35E399C4D9 Q47595147-BAFEF2A6-F91E-4322-873C-84FA90E49D50 Q47761939-03389B5F-E2C0-4C84-8785-0F34FBB6A48D Q49722022-45F87DF1-C899-4995-A34E-AE3D10C06399 Q50221512-0E5FEF58-4CA6-4C5F-A515-D14F67F427EC

P2860

Drug-induced QT interval prolongation: mechanisms and clinical management

http://www.wikidata.org/entity/Q33949538

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Drug-induced QT interval prolongation: mechanisms and clinical management

@ast

Drug-induced QT interval prolongation: mechanisms and clinical management

@en

type

label

Drug-induced QT interval prolongation: mechanisms and clinical management

@ast

Drug-induced QT interval prolongation: mechanisms and clinical management

@en

prefLabel

Drug-induced QT interval prolongation: mechanisms and clinical management

@ast

Drug-induced QT interval prolongation: mechanisms and clinical management

@en

P1433

Q33949538-F05205AA-9EB8-48F0-9A6A-BAF02377316D

P1476

Q33949538-CCA12165-F219-4809-A6CA-3CD27262CEEF

P2093

Q33949538-18BB0D61-1BCA-4357-A61E-73AC9BB05190

Q33949538-5A86DB99-E154-465D-859A-EDDF366A48D4

Q33949538-A6744607-746A-4A90-8228-7F4A5DFCF6BA

P2860

Q33949538-07412735-4560-469B-B416-B7EABD9441A5

Q33949538-106EBDFB-3CD2-454A-A14E-8AA4FA311284

Q33949538-133C7A00-121B-4855-AA55-F65C6815C1C8

Q33949538-13D5AEB9-5C6B-4AF1-9A5E-975F9EB2557A

Q33949538-14D0E559-1376-4C90-A420-2403DAABB534

Q33949538-1868A304-DA8A-4F60-9886-150E5F5BBAA9

Q33949538-18B54894-BC44-4F47-8067-3D3C1264946D

Q33949538-1CAAF585-1F82-492E-87DA-EADCD6BECC80

Q33949538-1DA920A9-6BA4-4C21-84CD-6C2408C22D08

Q33949538-20EC9DF7-AEBA-45F4-AECA-D09B7108F43A

P304

Q33949538-E2BA0E44-01CC-4C75-B545-7920E8AABBA0

P31

Q33949538-7ADE1511-E8A4-4C13-B14E-50C032116FF8

P356

Q33949538-680E7F18-D8A7-4B50-A061-81715B0A0CC0

P433

Q33949538-BBCA0B3E-8398-4E43-B02C-3FA4B6FC2E62

P478

Q33949538-CED66D9A-312D-4DCE-9DE8-4A9A971A2E95

P577

Q33949538-8FEDC8B5-72A0-46DF-9C07-D66A8D50810D

P5875

Q33949538-AA9A2FB2-E4E4-48F4-92DE-3F28451ADF2B

P698

Q33949538-3B88078F-FAB9-44FC-B3A1-774B4A90260A

P932

Q33949538-C2E5011A-4905-40F7-8C58-61BF99A2D357

P356

2042098612454283

P1433

Therapeutic advances in drug safety

P1476

Drug-induced QT interval prolongation: mechanisms and clinical management

@en

P2093

Jeffrey M Schussler

http://www.w3.org/2001/XMLSchema#string

Manish D Assar

http://www.w3.org/2001/XMLSchema#string

Senthil Nachimuthu

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of cardiotoxicity of halofantrine

Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2

The genetic basis of long QT and short QT syndromes: a mutation update

Torsades de pointes occurring in association with terfenadine use

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.

Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.

Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.

Clinical and therapeutic aspects of congenital and acquired long QT syndrome.

Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.

P304

241-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042098612454283

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234029809

http://www.w3.org/2001/XMLSchema#string

P698

25083239

http://www.w3.org/2001/XMLSchema#string

P932

4110870

http://www.w3.org/2001/XMLSchema#string